Latest Period
Q4 2025
Security Snapshot
EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) Institutional Ownership
CUSIP: 29842P105
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
35
Shares (Excl. Options)
13,830,451
Price
$7.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, no par value
- Symbol
- EPRX on Nasdaq
- Shares outstanding
- 52,146,078
- Price per share
- $7.18
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 13,830,451
- Total reported value
- $104,211,571
- % of total 13F portfolios
- 0%
- Share change
- +517,128
- Value change
- +$5,872,102
- Number of holders
- 35
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 29842P105.
- 35 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 35 to 18 between Q4 2025 and Q1 2026.
- Reported value moved from $104,211,571 to $18,842,193.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 35 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 29842P105?
CUSIP 29842P105 identifies EPRX - EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29842P105:
Significant Owners of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Freedman Joseph S. | 9% | -12% | $47,037,881 | +$2,495,500 | 5,843,215 | +5.6% | Joseph S. Freedman | 13 Mar 2026 |
| Beutel, Goodman & Co Ltd. | 8% | $23,947,504 | 4,058,899 | Beutel, Goodman & Co Ltd. | 30 Sep 2025 | |||
| MANCHESTER MANAGEMENT CO LLC | 7.7% | -17% | $28,829,481 | -$6,384,994 | 4,015,248 | -18% | Morgan C. Frank | 31 Mar 2026 |
| DISBROW ROBERT | 7% | $21,052,085 | 3,568,150 | Robert Disbrow | 30 Sep 2025 |
As of 31 Dec 2025, 35 institutional investors reported holding 13,830,451 shares of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX). This represents 27% of the company’s total 52,146,078 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 7.1% | 3,709,373 | -8.6% | 0.17% | $27,926,000 |
| Vivo Capital, LLC | 2.6% | 1,350,000 | 0% | 0.66% | $10,192,500 |
| Balyasny Asset Management L.P. | 2.6% | 1,350,000 | 0% | 0.02% | $10,192,500 |
| SCOTIA CAPITAL INC. | 2.5% | 1,286,183 | +0.65% | 0.04% | $9,604,679 |
| GREAT POINT PARTNERS LLC | 2.3% | 1,200,000 | 0% | 2.9% | $9,060,000 |
| Point72 Asset Management, L.P. | 1.4% | 712,104 | 0.01% | $5,376,437 | |
| Ikarian Capital, LLC | 1.2% | 610,000 | 0.6% | $4,605,500 | |
| Squadron Capital Management LLC | 0.96% | 500,000 | 0% | 1.7% | $3,775,000 |
| Ally Bridge Group (NY) LLC | 0.76% | 397,895 | -57% | 4.8% | $3,004,107 |
| Velan Capital Investment Management LP | 0.68% | 352,000 | 0% | 1.5% | $2,657,600 |
| Affinity Asset Advisors, LLC | 0.58% | 300,000 | 0% | 0.16% | $2,265,000 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.53% | 278,064 | 0% | $2,090,765 | |
| BANK OF AMERICA CORP /DE/ | 0.49% | 253,321 | +456% | 0% | $1,912,574 |
| UBS Group AG | 0.42% | 220,024 | +130% | 0% | $1,661,181 |
| ROYAL BANK OF CANADA | 0.38% | 196,277 | -54% | 0% | $1,482,000 |
| SummitTX Capital, L.P. | 0.34% | 175,948 | 0.04% | $1,328,407 | |
| MARSHALL WACE, LLP | 0.3% | 158,133 | 0% | $1,193,905 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.3% | 156,331 | 0.03% | $1,180,299 | |
| ACADIAN ASSET MANAGEMENT LLC | 0.3% | 155,766 | +628% | 0% | $1,168,000 |
| INGALLS & SNYDER LLC | 0.15% | 77,400 | +31% | 0.02% | $584,000 |
| GOLDMAN SACHS GROUP INC | 0.11% | 58,058 | +45% | 0% | $438,338 |
| CIBC WORLD MARKET INC. | 0.11% | 58,050 | +287% | 0% | $436,536 |
| RAYMOND JAMES FINANCIAL INC | 0.1% | 52,972 | +59% | 0% | $399,939 |
| Quadrature Capital Ltd | 0.08% | 43,186 | 0% | $325,625 | |
| BANK OF MONTREAL /CAN/ | 0.07% | 37,250 | 0% | 0% | $280,083 |
Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, no par value (EPRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,947,875 | $18,842,193 | +$7,830,539 | $7.24 | 18 |
| 2025 Q4 | 13,830,451 | $104,211,571 | +$5,872,102 | $7.55 | 35 |
| 2025 Q3 | 12,813,323 | $75,287,324 | +$63,953,992 | $5.90 | 27 |
| 2025 Q2 | 1,970,076 | $10,889,810 | -$1,049,985 | $5.76 | 14 |
| 2025 Q1 | 2,167,593 | $7,087,336 | +$1,118,946 | $3.28 | 11 |
| 2024 Q4 | 1,826,270 | $5,634,759 | +$50,501 | $3.17 | 9 |
| 2024 Q3 | 1,798,968 | $4,545,745 | +$185,000 | $2.63 | 8 |
| 2024 Q2 | 1,727,190 | $4,433,025 | +$4,433,025 | $2.58 | 8 |